Cyclodextrin inclusion complexes improving antibacterial drug profiles: an update systematic review

Today's cyclodextrin,

Today’s cyclodextrin:

Improving antibacterial drugs’ physicochemical characteristics and biological activities has been in the focus of CD research for a long time. This extensive review by deals with this topic showing the biological results rvealing the antibacterial effect of the inclusion complexes was extensively improved. Cyclodextrins can enhance the therapeutic effects of antibiotics already existing on the market, natural products and synthetic molecules. Overall, CDs as drug-delivery vehicles have been shown to improve antibiotics solubility, stability, and bioavailability, leading to enhanced antibacterial activity.

Cyclodextrin inclusion complexes improving antibacterial drug profiles: an update systematic review | Future Microbiology (futuremedicine.com)

Antibiotics in the clinical pipeline as of December 2022

drug discovery,

Do you think we are putting enough effort in developing novel antibiotics?
The need for new antibacterial drugs to treat the increasing global prevalence of drug-resistant bacterial infections has clearly attracted global attention, with a range of existing and upcoming funding, policy, and legislative initiatives designed to revive antibacterial R&D. Despite the promising early-stage antibacterial pipeline, it is essential to maintain funding for antibacterial R&D and to ensure that plans to address late-stage pipeline issues succeed.

See the full article here:

Antibiotics in the clinical pipeline as of December 2022 | The Journal of Antibiotics (nature.com)